Epidermal growth factor receptor inhibitors (EGFRi) have exhibited promising clinical
outcomes in the treatment of various cancers. However, their widespread application has …

Despite recent development in targeted therapies, lung cancer still remains the leading
cause of cancer death. Therefore, a better understanding of its pathogenesis and …

We present a case of a woman with epidermal growth factor receptor (EGFR)-mutated lung
adenocarcinoma who received gefitinib for 2 years and obtained a partial response. The …

Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) have a good
clinical efficacy in lung adenocarcinoma harboring activating-mutation EGFR. Such EGFR …

Purpose: The response to immune checkpoint inhibitors (ICI) often differs between genders
in non–small cell lung cancer (NSCLC), but metanalyses results are controversial, and no …

Our body is constantly exposed to pathogens or external threats, but with the immune
response that our body can develop, we can fight off and defeat possible attacks or …

Lung cancer is the leading cause of cancer deaths worldwide, with a 5-year survival rate of
about 18%. Thus, there is a great need for novel therapeutic approaches to treat non-small …

肺癌是癌症相关死亡的主要原因. 目前, 肺癌的发病率正在下降, 但患者的生存率仍然较低.
肺癌中超过85% 是非小细胞肺癌(non-small cell lung cancer, NSCLC), 超过60% 的NSCLC …

Breast cancer is the most common malignancy in women, and lung cancer, the leading
cause of cancer-related mortality in the United States, is the most common subsequent …

Despite the progress made in the management of lung adenocarcinoma (LUAD), the overall
prognosis for LUAD individuals remains suboptimal. While the role of cell polarity in tumor …